Liposomes

Sr. Carrier System Composition Method Drug Loaded Pharmacological Issue Reference
No.
1. Pembrolizumab  1,2-Dipalmitoyl-sn-glycero-3- Thin-Film Pembrolizumab  Head and neck squamous cell [1]
Liposome phospho-rac-(1-glycerol) Rehydration carcinoma (HNSCC).
sodium salt (DPPG)  Liposomes were developed due to
 1,2-dioleoyl-sn-glycero-3- reduced efficacy of pembrolizumab
phosphoethanolamine (DOPE) due to rapid biodegradation and
 Cholesterol clearance.
 Dichloro-methane (DCM)
 Methanol (3:1 v/v).
2. Paclitaxel  Lecithin Film Paclitaxel  Non-small cell lung cancer (NSCLC) [2]
Liposome  Cholesterol Dispersion  Paclitaxel liposomes increase drug
(Lipusu)  Ethanol method exposure by maintaining high
followed by a concentrations in tumor cells and
lyophilization reduce the incidence of drug-induced
technique toxicity.
3. Inhaled Dry  Soybean phosphatidylcholine Thin-Film Azithromycin  Chronic lower respiratory tract [3]
Powder (SPC) Hydration infection
Liposomal  Dimethyl dioctadecyl  Liposomal formulation aided in
Azithromycin ammonium bromide (DDAB): targeting drug to the site of action
 D-α-tocopheryl polyethylene and minimizing possible systemic
glycol succinate (TPGS) side effects, and resulted in improved
 Chloroform clinical outcomes.
 Methanol
4. Carmustine-  Soya Lecithin Thin-Film Carmustine  Glioblastoma [4]
Loaded  Cholesterol Hydration  Carmustine-loaded liposomes, due to
Liposome  Chloroform their nano size (< 200 nm) can easily
penetrate the cancer cells and cause
toxicity.
5. Lipid-Like  GEM diesters Thin-Film Gemcitabine  Pancreatic cancer [5]
Gemcitabine  1,2-dimyristoyl-sn-glycero-3- Dispersion  Liposomes enhanced cellular uptake
Diester-Loaded phosphocholine (DMPC) and cell apoptosis in cancer cells.
 Liposomes  (or HSPC or DOPC)
 Cholesterol
 DSPE-PEG2000
 Chloroform
6. Etoposide  Soybean phosphatidylcholine Thin-Film Etoposide  Small Cell Lung Cancer [6]
Liposomes (SPC) Evaporation  Liposomal formulation exhibited
 DSPE-mPEG2000 strong cytotoxic activity and less
 Cholesterol bone marrow suppression.
 Chloroform
 Methanol
7. Liposome-  1, 2-dipalmitoyl-Sn-glycero- 3- Thin-Film Bevacizumab  Ocular Neovascularization [7]
encapsulated phosphocholine (DPPC) Hydration  Liposomal formulation was found to
Bevacizumab  Cholesterol be effective at inhibiting
 DSPE-PEG-2000 angiogenesis.
 Chloroform
8. Telmisartan-  Soya lecithin Thin-Film Telmisartan  Breast Cancer [8]
Loaded  Cholesterol Hydration  Liposomes showed enhanced
Liposomes  Chloroform treatment efficacy and reduced side
effects.
9. Mannose-  Egg phosphatidylcholine Thin-Film Celastrol  Rheumatoid Arthritis [9]
modified  Cholesterol Hydration  Liposomes exhibited low cytotoxicity
Celastrol  DSPE-PEG2000, and also reduced inflammatory
Liposomes  DSPE-PEG2000-MAN factors.
 Methanol
10. Glucose-  Soybean phosphatidylcholine Thin Film Quercetin  Neurodegenerative Diseases (NDDs) [10]
modified (SPC) Hydration  QU-liposome enhanced the
Quercetin-  Cholesterol Sonication antioxidant and neuroprotective
Loaded  Glucose ligand effects of quercetin.
Liposomes  Chloroform
(QU–Glu–Lip)  Methanol

Niosomes
Sr. Carrier System Composition Method Drug Loaded Pharmacological Issue Reference
No.
1. Tamoxifen-  Cholesterol Thin-Layer Tamoxifen  Breast Cancer [1]
Curcumin  Sorbitan monooleate (Span 80) Hydration Curcumin  Niosomes developed for apoptosis
Loaded  Chloroform induction, cell cycle arrest and anti-
Niosomes cancer potential against MCF-7 Cancer
Cells
2. Simvastatin  Surfactant (Span 20, 40, 60 and Thin-Film Simvastatin  Breast Cancer [2]
Niosomes 80) Hydration  Niosomal delivery of simvastatin
 Cholesterol improved the drug concentration in
 Chloroform MDA-MB-231cancer cells and also
provided sustained-release of
simvastatin.
3. Ciprofloxacin-  Polyoxyethylene (20) sorbitan Thin Layer Ciprofloxacin  Urinary Tract Infections caused by [3]
Loaded trioleate (Tween 85) Evaporation Escherichia coli and Staphylococcus
Niosomes  Sorbitan monooleate (Span 80) (TLF) aureus Biofilm Formation
 Chloroform
 Ethanol
4. Cap-Que  Cholesterol Thin-Film Captopril  Hypertension [4]
Loaded  Sorbitan monostearate (Span 60) Hydration Quercetin  Niosomal delivery improves the
Niosomes  Steryl amine (charge inducer) (cap-que) pharmacophoric profile of the hybrid
 Methanol (cap-que) providing improved treatment
 Chloroform outcomes for hypertensive patients.
5. Resveratrol-  Sorbitan monostearate (Span 60) Thin-Film Resveratrol  Pancreatic cancer [5]
Loaded  Polyoxyethylene (80) sorbitan Hydration  Niosomal formulations aided in targeted
Magnetic monooleate (Tween 80) delivery of Resveratrol to Capan-1 cell
Niosomes  Cholesterol pancreatic cancer
 Chloroform
 Methanol
6. TCH- Loaded  Cholesterol Thin-Film Tetracycline  Wound healing [6]
Chitosan-  Polyoxyethylene sorbitan Hydration hydrochloride  Niosomal formulations exhibited 2-fold
based monostearate (Tween 60) (TCH) higher antibacterial and anti-biofilm
Nanoniosome  Sorbitan monostearate (Span® activity.
 60)
 Chloroform
7. Cyclosporine-  Cholesterol Thin-Film Cyclosporine  Psoriasis [7]
Loaded  Span 60 Hydration  Niosomal nanocarriers provide
Niosomal  Methanol improved skin penetration and
Nanocarriers  Chloroform deposition in psoriasis.
8. Cationically -  Sorbitan monostearate (Span 60) Thin-Film Nintedanib  Non-small cell lung cancer (NSCLC) [8]
modified  Cholesterol Hydration  Niosomes can increase the
Inhalable  Chloroform chemotherapeutic activity of nintedanib
Nintedanib  Methanol by pulmonary administration.
Niosomes
9. Doxycycline-  Sorbitan monostearate (Span 60) Thin-Layer Doxorubicin  Infection-associated Prostate Cancer [9]
Loaded  Polyoxyethylene sorbitan Hydration  Niosomal formulation exhibited
Niosome monostearate (Tween 60) promising anticancer and antibiotic
 Cholesterol activity in prostate cancer cells (PC3).
 Chloroform
10. Amikacin-  Sorbitan monostearate (Span 60) Thin-Film Amikacin  Multi-drug Resistant Infections caused [10]
Loaded  Polyoxyethylene sorbitan Hydration by Klebsiella pneumoniae
Niosome monostearate (Tween 60)  Amikacin niosomes displayed higher
 Cholesterol antibiotic and antibiofilm activity and
 Chloroform less toxicity.

References:

1- Bobtina, N., Alhawamdeh, M., Habas, K., Isreb, M., Aburas, B., Harris, A. T., ... & Anderson, D. (2024). Genoprotective role of
pembrolizumab liposome in isolated lymphocytes from head and neck squamous cell carcinoma patients compared to those from healthy
individuals in vitro. Nanotoxicology, 1-14.
2- Li, R., Liang, H., Li, J., Shao, Z., Yang, D., Bao, J., ... & Mu, X. (2024). Paclitaxel liposome (Lipusu) based chemotherapy combined
with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study. BMC cancer, 24(1), 107.
3- Bashi, Y. H. D., Ali, A., Al Ayoub, Y., Assi, K. H., Mairs, R., McCarthy, H. O., ... & Kett, V. L. (2024). Inhaled dry powder liposomal
azithromycin for treatment of chronic lower respiratory tract infection. International Journal of Pharmaceutics, 653, 123841.
 4- Rani, V., Venkatesan, J., & Prabhu, A. (2024). Carmustine-Loaded Liposomal Delivery Effectively Targets Malignant Glioma Cells and
Seizes Endothelial Sprouting In vitro. Journal of Cluster Science, 1-11.
5- Wang, X., Lu, H., Luo, F., Wang, D., Wang, A., Wang, X., ... & Xia, G. (2024). Lipid-like gemcitabine diester-loaded liposomes for
improved chemotherapy of pancreatic cancer. Journal of Controlled Release, 365, 112-131.
6- Huang, R., Chen, H., Pi, D., He, X., Yu, C., & Yu, C. (2024). Preparation of etoposide liposomes for enhancing antitumor efficacy on
small cell lung cancer and reducing hematotoxicity of drugs. European Journal of Pharmaceutics and Biopharmaceutics, 114239.
7- Malakouti–Nejad, M., Monti, D., Burgalassi, S., Bardania, H., Elahi, E., & Morshedi, D. (2024). A comparison between the effects of
two liposome-encapsulated bevacizumab formulations on ocular neovascularization inhibition. Colloids and Surfaces B: Biointerfaces,
234, 113708.
8- Singh, A., Maheshwari, S., Kumar, R., Yadav, J. P., & Kumari, R. (2024). Telmisartan-loaded liposomes: An innovative weapon against
breast cancer. Intelligent Pharmacy.
9- Si, J., Guo, R., Zhang, L., Liu, W., Kong, L., Liu, Y., ... & Li, X. (2024). Mannose-modified celastrol liposomes targeted activated
macrophages for rheumatoid arthritis treatment in vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology, 91,
105185.
10- Chen, J., Chen, J., Yu, P., Yang, C., Xia, C., Deng, J., ... & Yang, X. (2024). A Novel Quercetin Encapsulated Glucose Modified
Liposome and Its Brain-Target Antioxidative Neuroprotection Effects. Molecules, 29(3), 607.

Niosomes
1- Fatemizadeh, M., Tafvizi, F., Shamsi, F., Amiri, S., Farajzadeh, A., & Akbarzadeh, I. (2022). Apoptosis induction, cell cycle arrest and
anti-cancer potential of tamoxifen-curcumin loaded niosomes against MCF-7 cancer cells. Iranian Journal of Pathology, 17(2), 183.
2- Akbarzadeh, I., Saremi Poor, A., Yaghmaei, S., Norouzian, D., Noorbazargan, H., Saffar, S., ... & Bakhshandeh, H. (2020). Niosomal
delivery of simvastatin to MDA-MB-231 cancer cells. Drug Development and Industrial Pharmacy, 46(9), 1535-1549.
3- Maurizi, L., Forte, J., Ammendolia, M. G., Hanieh, P. N., Conte, A. L., Relucenti, M., ... & Longhi, C. (2022). Effect of Ciprofloxacin-
loaded niosomes on escherichia coli and staphylococcus aureus biofilm formation. Pharmaceutics, 14(12), 2662.
4- Sayyad, N., Maji, R., Omolo, C. A., Ibrahim, U. H., Pathan, T. K., Devnarain, N., ... & Singh, S. (2021). Development of niosomes for
encapsulating captopril-quercetin prodrug to combat hypertension. International Journal of Pharmaceutics, 609, 121191.
5- Firouzi Amandi, A., Bahmanyar, Z., Dadashpour, M., Lak, M., Natami, M., Döğüş, Y., ... & Adeli, O. A. (2024). Fabrication of magnetic
niosomal platform for delivery of resveratrol: potential anticancer activity against human pancreatic cancer Capan-1 cell. Cancer Cell
International, 24(1), 46.
6- Pourseif, T., Ghafelehbashi, R., Abdihaji, M., Radan, N., Kaffash, E., Heydari, M., ... & Ren, Q. (2023). Chitosan-based nanoniosome for
potential wound healing applications: Synergy of controlled drug release and antibacterial activity. International Journal of Biological
Macromolecules, 230, 123185.
7- Pandey, S. S., Shah, K. M., Maulvi, F. A., Desai, D. T., Gupta, A. R., Joshi, S. V., & Shah, D. O. (2021). Topical delivery of
cyclosporine loaded tailored niosomal nanocarriers for improved skin penetration and deposition in psoriasis: Optimization, ex vivo and
animal studies. Journal of Drug Delivery Science and Technology, 63, 102441.
8- K Shukla, S., Nguyen, V., Goyal, M., & Gupta, V. (2022). Cationically modified inhalable nintedanib niosomes: enhancing therapeutic
activity against non-small-cell lung cancer. Nanomedicine, 17(13), 935-958.
9- Akbarzadeh, I., Yaraki, M. T., Bourbour, M., Noorbazargan, H., Lajevardi, A., Shilsar, S. M. S., ... & Mousavian, S. M. (2020).
Optimized doxycycline-loaded niosomal formulation for treatment of infection-associated prostate cancer: An in-vitro investigation.
Journal of Drug Delivery Science and Technology, 57, 101715.
10- Rahmati, M., Babapoor, E., & Dezfulian, M. (2022). Amikacin-loaded niosome nanoparticles improve amikacin activity against
antibiotic-resistant Klebsiella pneumoniae strains. World Journal of Microbiology and Biotechnology, 38(12), 230.